SCHEMBL7180488

SCHEMBL7180488

COc1cccc(OC)c1C(=O)c1ccccc1[P](=O)C(=O)c1c(C)cc(C)cc1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 1/20 0.43
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
KCNK3 O14649 3/20 0.38
KCNK9 Q9NPC2 3/20 0.38
RAB9A P51151 2/20 0.38
NPC1 O15118 1/20 0.38
POLB P06746 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
IDO1 P14902 1/20 0.36
TDO2 P48775 1/20 0.36
KCNB1 Q14721 1/20 0.36
KCNMA1 Q12791 1/20 0.36
MAPT P10636 1/20 0.36
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7188505 0.95 ABCB1 (0.43) ABCB1KMT2AMEN1KCNK3KCNK9
SCHEMBL7180828 0.92 ABCB1 (0.40) ABCB1KMT2AMEN1RAB9ANPC1
SCHEMBL7179534 0.90 ABCB1 (0.39) ABCB1KMT2AMEN1RAB9ANPC1
SCHEMBL7175433 0.87 KCNK3 (0.39) KMT2AMEN1KCNK3KCNK9RAB9A
SCHEMBL7178052 0.87 ABCB1 (0.40) ABCB1KMT2AMEN1RAB9ANPC1
SCHEMBL7177390 0.86 CA12 (0.41) KMT2AKCNK3KCNK9RAB9APOLB
SCHEMBL7183573 0.86 KMT2A (0.39) ABCB1KMT2AMEN1KCNK3KCNK9
SCHEMBL7180500 0.86 KMT2A (0.39) ABCB1KMT2AMEN1KCNK3KCNK9
SCHEMBL7181666 0.86 KCNK3 (0.37) ABCB1KMT2AMEN1KCNK3KCNK9
SCHEMBL710804 0.86 ABCB1 (0.44) ABCB1KMT2AMEN1KCNK3KCNK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 ABCB1 2890/4885KMT2A 1586/4885MEN1 2312/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 ABCB1 3708/4885KMT2A 956/4885MEN1 2263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.